These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
554 related articles for article (PubMed ID: 32585765)
1. A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient. Thammathiwat T; Tungsanga S; Tiankanon K; Torvorapanit P; Chumpangern W; Udomkarnjananun S; Avihingsanon Y; Sriprasart T; Srisawat N; Jutivorakool K; Paitoonpong L; Putcharoen O; Townamchai N Transpl Infect Dis; 2021 Feb; 23(1):e13388. PubMed ID: 32585765 [TBL] [Abstract][Full Text] [Related]
2. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial. Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502 [TBL] [Abstract][Full Text] [Related]
3. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989 [TBL] [Abstract][Full Text] [Related]
4. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363 [TBL] [Abstract][Full Text] [Related]
5. Modification of immunosuppressive agents in a kidney transplant recipient with COVID-19 and acute kidney injury. Vongchaiudomchoke T; Sawangduan V; Sinpanee T; Chalermphunchai N; Lelamali K; Noppakun K J Infect Dev Ctries; 2021 Sep; 15(9):1273-1276. PubMed ID: 34669595 [TBL] [Abstract][Full Text] [Related]
6. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Hanna CR; Blyth KG; Burley G; Carmichael S; Evans C; Hinsley S; Khadra I; Khoo S; Lewsley LA; Jones RR; Sharma R; Taladriz-Sender A; Thomson EC; Scott JT Trials; 2020 Nov; 21(1):935. PubMed ID: 33213530 [TBL] [Abstract][Full Text] [Related]
8. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Çalık Başaran N; Uyaroğlu OA; Telli Dizman G; Özışık L; Şahin TK; Taş Z; İnkaya AÇ; Karahan S; Alp Ş; Alp A; Metan G; Zarakol P; Sain Güven G; Öz ŞG; Topeli A; Uzun Ö; Akova M; Ünal S Turk J Med Sci; 2021 Apr; 51(2):411-420. PubMed ID: 32718127 [TBL] [Abstract][Full Text] [Related]
9. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial. Li J; Zhang C; Wu Z; Wang G; Zhao H Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657 [TBL] [Abstract][Full Text] [Related]
10. A Favipiravir-induced Fever in a Patient with COVID-19. Kurita T; Ishida K; Muranaka E; Sasazawa H; Mito H; Yano Y; Hase R Intern Med; 2020; 59(22):2951-2953. PubMed ID: 33191372 [TBL] [Abstract][Full Text] [Related]
11. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Pereira MR; Mohan S; Cohen DJ; Husain SA; Dube GK; Ratner LE; Arcasoy S; Aversa MM; Benvenuto LJ; Dadhania DM; Kapur S; Dove LM; Brown RS; Rosenblatt RE; Samstein B; Uriel N; Farr MA; Satlin M; Small CB; Walsh TJ; Kodiyanplakkal RP; Miko BA; Aaron JG; Tsapepas DS; Emond JC; Verna EC Am J Transplant; 2020 Jul; 20(7):1800-1808. PubMed ID: 32330343 [TBL] [Abstract][Full Text] [Related]
12. Kidney Transplantation and COVID-19: Two Case Reports. Tekin S; Özdoğan H; Demir MK; Soultan H; Zafar S Transplant Proc; 2021 May; 53(4):1207-1210. PubMed ID: 33451758 [TBL] [Abstract][Full Text] [Related]
13. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19. Ömeroğlu ŞK; Temel F; Altun D; Öztop B Turk J Med Sci; 2021 Dec; 51(6):2827-2834. PubMed ID: 34165273 [TBL] [Abstract][Full Text] [Related]
14. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment. Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246 [TBL] [Abstract][Full Text] [Related]
16. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. Fontana F; Alfano G; Mori G; Amurri A; Tei L; Ballestri M; Leonelli M; Facchini F; Damiano F; Magistroni R; Cappelli G Am J Transplant; 2020 Jul; 20(7):1902-1906. PubMed ID: 32324331 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880 [TBL] [Abstract][Full Text] [Related]
18. Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia. Tatar E; Karatas M; Bozaci I; Ari A; Acar T; Simsek C; Yildirim AM; Yildirim O; Uslu A Transfus Apher Sci; 2020 Dec; 59(6):102904. PubMed ID: 32807652 [No Abstract] [Full Text] [Related]
19. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712 [TBL] [Abstract][Full Text] [Related]
20. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series. Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854 [No Abstract] [Full Text] [Related] [Next] [New Search]